AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-06-11	0.8880 €	-2.42%	206,532
26-06-10	0.9100 €	+1.79%	200,138
26-06-09	0.8940 €	+1.59%	186,613
26-06-08	0.8800 €	-3.30%	433,362
26-06-05	0.9100 €	-2.15%	256,465

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-06-11 EDT			5-day change	1st Jan Change
0.8880 ^EUR	-2.42%		-6.33%	-42.19%

06-10	AB Science presents new data on Masitinib
05-17	AB Science S.A. announced that it has received $2.989368 million in funding	CI

Market Cap	67.97M 78.32M 62.65M 58.7M 110M 7.5B 112M 747M 289M 3.61B 294M 288M 12.57B	P/E Ratio 2025 *	-	P/E Ratio 2026 *	-
Enterprise Value	67.97M 78.32M 62.65M 58.7M 110M 7.5B 112M 747M 289M 3.61B 294M 288M 12.57B	EV / Sales 2025	95.4x	EV / Sales 2026 *	56.6x
Free-Float	67.54%	Yield 2025 *	-	Yield 2026 *	-

06-10	AB Science presents new data on Masitinib
05-17	AB Science S.A. announced that it has received $2.989368 million in funding	CI
05-13	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-03	AB Science S.A. announced that it expects to receive $2.989368 million in funding	CI
04-29	Airbus, Pernod Ricard, Sopra Steria, TotalEnergies, TP... stocks to watch today in Paris
04-29	AB Science announces successful capital increase
04-28	Air Liquide, Nexans, AB Science... stocks to watch today in Paris
04-28	AB Science Reaches Maturity Extension Deal with Lenders	MT
04-27	Vinci, Lumibird, SergeFerrari... stocks to watch tomorrow in Paris
04-27	AB Science announces major agreement with creditors
04-27	AB Science SA Announces Final Agreement on Renegotiation of Repayment Terms of Loans With Financial Creditors	CI
04-21	Thales, Vivendi, Mercialys, GTT... stocks to watch today in Paris
04-21	Positive data for AB Science's masitinib published on medRxiv

06-09	AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS	GL
06-02	AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share	GL
05-26	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of EUR4.00 per share	AQ
05-25	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share	GL
05-13	AB Science : Annual financial results as of 31 December, 2025	PU

AB Science Stock

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

06-10	Bourse : Airbus veut rebondir sur le SCAF, Legrand se renforce, le marché attend Oracle
06-10	AB Science présente de nouvelles données sur son Masitinib
06-10	Ça ne respire pas la sérénité à Wall Street
06-09	AB Science présentera, lors du congrès annuel 2026 de l'ENCALS, les données de survie issues du programme clinique du masitinib dans la SLA
06-02	AB Science : Stonegate Capital Partners actualise sa couverture de l'action AB Science avec un objectif de cours de 4,25 EUR par action

1 day	-2.42%
1 week	-6.33%
Current month	-7.88%
1 month	-7.40%
3 months	-31.90%
6 months	-25.38%
Current year	-42.19%

1 week	0.87	0.93
1 month	0.87	1.05
Current year	0.87	1.61
1 year	0.87	1.73
3 years	0.77	4.97
5 years	0.77	16.68
10 years	0.77	21.75

Manager	Title	Age	Since
Alain Moussy CEO	Chief Executive Officer	-	2001-07-10
Laurent Guy DFI	Director of Finance/CFO	-	2009-11-19
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	2018-03-31

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	2001-07-10
Patrick Moussy BRD	Director/Board Member	-	2011-09-19
Cécile de Guillebon BRD	Director/Board Member	64	2021-06-26

Date	Insider	Type	Main position	Quantity	% Market Cap.
05-19	Alain Moussy	Sell	Chief Executive Officer	-573	0.0009%
21-02-08	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
21-02-01	Jean-Pierre Kinet	Sell	Founder	12,904	0.0280%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-2.42%	-6.33%	-24.87%	-79.18%	80.47M
MERCK & CO., INC.	+1.40%	+5.28%	+48.44%	+9.08%	294B
MERCK KGAA	-0.77%	+1.42%	+16.37%	-19.67%	68.54B
HALOZYME THERAPEUTICS, INC.	+0.33%	+1.30%	+31.54%	+108.27%	8.36B
KYOWA KIRIN CO., LTD.	+1.95%	+4.93%	-1.40%	-10.21%	7.77B
SK BIOPHARMACEUTICALS CO., LTD.	+2.43%	+0.11%	-4.74%	+19.76%	4.45B
YUHAN CORPORATION	-0.65%	-6.26%	-28.80%	+32.81%	3.77B
BETTA PHARMACEUTICALS CO., LTD.	+4.33%	+10.46%	-16.19%	+2.15%	3.14B
SUPERNUS PHARMACEUTICALS, INC.	+1.02%	+3.44%	+36.95%	+30.82%	2.62B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+1.17%	-3.99%	-3.56%	-21.04%	1.89B
Average	+0.88%	+1.36%	+5.37%	+7.28%	39.48B
Weighted average by Cap.	+1.02%	+3.38%	+39.34%	+6.08%

	2025	2026 *
Net sales	1.1M 1.27M 1.01M 950K 1.78M 121M 1.81M 12.1M 4.68M 58.5M 4.76M 4.66M 203M	1.2M 1.38M 1.11M 1.04M 1.94M 132M 1.98M 13.19M 5.11M 63.82M 5.19M 5.08M 222M
Net income	-	-
Net Debt	-	-